Supplemental Hydrogen Plus PQQ for Mitochondrial Biomarkers and Brain Function in Elderly With Mild Cognitive Impairment

Last updated: December 3, 2024
Sponsor: University of Novi Sad, Faculty of Sport and Physical Education
Overall Status: Completed

Phase

N/A

Condition

Dementia

Mental Disability

Memory Loss

Treatment

Placebo

Supplement

Clinical Study ID

NCT05910047
A13-CH-2023
  • Ages > 65
  • All Genders

Study Summary

The goal of this randomized controlled double-blind parallel-group interventional trial is to evaluate the effects of dietary supplementation with molecular hydrogen and pyrroloquinoline quinone in elderly. The main questions it aims to answer are: (1) whether the supplementation affects biomarkers of mitochondrial function in serum, and (2) whether the supplementation affects cognition and brain metabolism. The participants will be subjected to take the dietary supplement during 6 weeks.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age > 65 years

  • MMSE scores ranged from 23-27

  • Informed consent signed

Exclusion

Exclusion Criteria:

  • Take part in exercise on a regular basis

  • Severe chronic disease and acute injuries

  • History of dietary supplement use during the past 4weeks

  • No consent to randomization

  • Participation in other studies

Study Design

Total Participants: 34
Treatment Group(s): 2
Primary Treatment: Placebo
Phase:
Study Start date:
September 01, 2023
Estimated Completion Date:
March 31, 2024

Connect with a study center

  • FSPE Applied Bioenergetics Lab

    Novi Sad, Vojvodina 21000
    Serbia

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.